Technical Verification and Assessment of Independent Validation of Biomarker Models for Endometriosis
Table 4
Levels of plasma biomarkers for endometriosis (all stages) versus controls.
Biomarker
Phase of cycle
Technical verification study
Validation study
Control
Endometriosis
p-value
Control
Endometriosis
p-value
CA-125 (U/ml)
All (no med)
15.61
19.28
13.00
20.00
(11.38-22.52)
(13.11-31.76)
(9.000- 16.00)
(14.00- 29.75)
Menstrual
19.49
20.56
NS
16.00
25.00
NS
(12.39-27.42)
(14.83-37.39)
(13.00- 23.50)
(13.00- 50.00)
Follicular
11.97
18.81
11.00
20.00
(9.859-16.13)
(12.16-29.44)
(8.000-17.00)
(11.75- 27.50)
Luteal
16.99
19.09
NS
12.00
19.00
(12.62-25.34)
(13.07-30.30)
(9.500- 13.00)
(15.00- 25.00)
Medication
N/A
N/A
N/A
9.000
15.00
(5.000- 12.00)
(9.750- 24.25)
VEGF (pg/ml)
All (no med)
41.44
40.82
NS
404.6
442.9
NS
(27.49- 58.59)
(28.52- 67.48)
(296.5-545.1)
(299.5-525.8)
Menstrual
43.69
44.57
NS
414.3
478.8
NS
(29.50- 54.13)
(30.62- 68.32)
(364.5-507.0)
(366.7-548.9)
Follicular
34.90
40.16
NS
400.0
424.0
NS
(25.17- 47.24)
(26.24- 61.08)
(278.5-581.5)
(254.4-521.2)
Luteal
56.22
38.05
NS
399.3
425.4
NS
(22.36-98.14)
(27.12-76.66)
(312.3-568.1)
(322.3-512.2)
Medication
N/A
N/A
N/A
368.7
376.5
NS
(217.2-490.4)
(263.4-449.7)
Annexin V
All (no med)
15.51
12.62
NS
7.322
10.16
NS
(ng/ml)
(11.41-20.56)
(8.860-19.59)
(3.568-49.06)
(3.051-43.65)
Menstrual
15.69
16.05
NS
4.519
6.031
NS
(13.94-18.17)
(9.640-22.31)
(2.031-25.69)
(2.387-26.19)
Follicular
15.06
12.67
NS
9.320
11.39
NS
(11.16-18.06)
(6.565-19.73)
(3.097-24.11)
(3.280-45.55)
Luteal
17.13
11.95
NS
17.05
10.40
NS
(8.490-24.31)
(8.610-18.25)
(3.881-63.47)
(3.364-60.85)
Medication
N/A
N/A
N/A
17.41
4.977
(4.489-57.69)
(2.523-11.56)
sICAM-1 (ng/ml)
All (no med)
154.8
147.7
NS
209.5
201.0
NS
(137.4-182.1)
(130.9-195.5)
(183.3- 236.2)
(171.0-226.2)
Menstrual
176.0
172.4
NS
195.7
201.0
NS
(135.0-246.9)
(130.9-298.0)
(186.0-230.2)
(167.8-226.7)
Follicular
149.0
153.2
NS
207.9
210.9
NS
(130.7-170.8)
(129.4-204.2)
(171.0-228.9)
(168.3-237.4)
Luteal
155.7
144.3
NS
227.4
186.8
NS
(134.1-177.1)
(130.7-164.6)
(189.1-241.2)
(171.8-216.3)
Medication
N/A
N/A
N/A
227.4
182.3
(197.7-260.3)
(163.8-204.7)
Glycodelin
All (no med)
29.06
34.76
NS
3.237
5.612
(ng/ml)
(11.90-47.50)
(16.20-85.41)
(1.254-11.30)
(2.250-17.83)
Menstrual
45.68
109.7
NS
7.242
19.68
NS
(37.62-109.1)
(39.79-190.7)
(2.312-19.86)
(10.46-40.30)
Follicular
12.87
17.42
NS
1.573
5.191
NS
(9.850-23.80)
(10.19-34.30)
(0.9660-7.578)
(2.126-9.351)
Luteal
31.13
43.26
NS
5.026
3.669
NS
(11.91-54.83)
(20.29-99.28)
(1.513-11.30)
(1.772-8.920)
Medication
N/A
N/A
N/A
0.9502
2.535
NS
(0.6382-3.436)
(1.032-4.221)
Data are presented as the median and interquartile range. Mann-Whitney test was performed for all phases combined, while Kruskal-Wallis with post-hoc Dunn’s analysis was done when biomarkers were analyzed according to cycle phase. No med = no medication. NS = not significant. N/A indicates that there was no medication cohort included in the technical verification study
